Zoetis (ZTS) Aperçu de l'action
Zoetis Inc. se consacre à la découverte, au développement, à la fabrication et à la commercialisation de médicaments, de vaccins, de produits et de services de diagnostic, de biodispositifs, de tests génétiques et de solutions de santé animale de précision pour l'industrie de la santé animale aux États-Unis et dans le monde. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 1/6 |
| Performances passées | 4/6 |
| Santé financière | 3/6 |
| Dividendes | 5/6 |
ZTS Community Fair Values
Create NarrativeSee what 265 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Zoetis Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$77.73 |
| Plus haut sur 52 semaines | US$158.30 |
| Plus bas sur 52 semaines | US$71.00 |
| Bêta | 0.73 |
| Variation sur 1 mois | 4.77% |
| Variation sur 3 mois | -4.41% |
| Variation sur 1 an | -50.37% |
| Variation sur 3 ans | -57.48% |
| Variation sur 5 ans | -61.86% |
| Évolution depuis l'introduction en bourse | 150.66% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Aug 19
ZTS: Reset Expectations And Product Stabilization Will Drive Long-Term Premium Recovery
Analysts have reduced the Zoetis fair value estimate from $160 to about $149, reflecting lower Street price targets and updated expectations for margins, competitive pressures, and slightly softer revenue growth assumptions. Analyst Commentary Street research on Zoetis over recent months has centered on recalibrated price targets, shifting ratings and concern around key product trends.Seeking Alpha • Aug 14
Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense
Summary Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross margins above 70%, after a severe multiyear drawdown. Competition, weaker U.S. companion animal sales, and reduced guidance have pressured ZTS, but its core profitability and market dominance remain intact. Management is aggressively repurchasing shares, capital returns are strong, and the balance sheet remains healthy despite $9B in long-term debt. I rate ZTS a Buy, as the risk/reward now favors value and dividend investors willing to tolerate near-term volatility and ongoing competitive headwinds. Read the full article on Seeking AlphaRecent updates
Mise à jour du récit • Aug 19
ZTS: Reset Expectations And Product Stabilization Will Drive Long-Term Premium Recovery
Analysts have reduced the Zoetis fair value estimate from $160 to about $149, reflecting lower Street price targets and updated expectations for margins, competitive pressures, and slightly softer revenue growth assumptions. Analyst Commentary Street research on Zoetis over recent months has centered on recalibrated price targets, shifting ratings and concern around key product trends.Seeking Alpha • Aug 14
Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense
Summary Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross margins above 70%, after a severe multiyear drawdown. Competition, weaker U.S. companion animal sales, and reduced guidance have pressured ZTS, but its core profitability and market dominance remain intact. Management is aggressively repurchasing shares, capital returns are strong, and the balance sheet remains healthy despite $9B in long-term debt. I rate ZTS a Buy, as the risk/reward now favors value and dividend investors willing to tolerate near-term volatility and ongoing competitive headwinds. Read the full article on Seeking Alpha
Mise à jour du récit • Aug 05
ZTS: Future Therapies And Legal Risks Will Shape Confidence Reset
The Zoetis analyst price target has been reduced by $10 to $80. Analysts attribute this change to lower sector valuations, softer trends in veterinary clinic visits, and rising competitive and pricing pressures highlighted across recent research updates.
Mise à jour du récit • Jul 22
ZTS: Premium Pet Health Portfolio Will Support Post Lawsuit And Guidance Reset
The analyst price target for Zoetis has been lowered, with the model fair value estimate moving from about $124.59 to $114.76, as analysts temper revenue growth assumptions while slightly improving profit margin and applying a lower future P/E multiple in response to a broad series of recent target cuts and more cautious commentary following Q1 results. Analyst Commentary Recent research on Zoetis shows a clear reset in expectations, with most analysts cutting price targets and recalibrating models after a difficult Q1 and updated guidance.
Nouveau récit • Jul 20
Wall Street Shock vs. Clinical Ground Truth — Is Zoetis a Value Trap or a Generational Mispricing?
Zoetis may not always look like the most high-tech, flashy ticker on Wall Street, but as a practicing veterinarian, my hands-on clinical experience tells a very different story. Sixteen years ago, when I first earned my veterinary license, the very first product I administered was Zoetis’ Vanguard vaccine.Mise à jour du récit • Jul 08
ZTS: Depressed Sentiment Will Set Up Long-Term Premium Portfolio Recovery
The analyst price target for Zoetis has been revised down from about $184 to $160. This reflects lower modeled revenue growth, a slightly higher discount rate, and reduced future P/E assumptions, which are partly tied to recent sector wide target cuts and concerns around key products and consumer trade down.Mise à jour du récit • Jun 24
ZTS: Future Pipeline And New Therapies Will Restore Confidence
Zoetis' analyst-derived fair value has been reset from $127.00 to $90.00 as analysts factor in weaker growth assumptions, a lower future P/E, and softer margin expectations following recent price target cuts and downgrades tied to investor confidence and competitive pressures. Analyst Commentary Recent research on Zoetis points to a more cautious mood, with several bearish analysts focusing on valuation pressure, softer execution and questions around the strength of future growth.Article d’analyse • Jun 20
Zoetis (ZTS) Stock Could Be 15.3% Undervalued After Class Action Lawsuits
Zoetis (ZTS) is back in focus after a series of securities class action lawsuits accused the company of misleading investors about weakening demand, safety concerns, and market share losses in its key companion animal products. See our latest analysis for Zoetis. At a share price of $78.71, Zoetis has seen pressure build over the past few months, with a 90 day share price return that declined 31.95% and a 1 year total shareholder return that declined 49.14%. Repeated class action...Mise à jour du récit • Jun 10
ZTS: Premium Pet Health Portfolio Will Support Post Selloff Earnings Reset
Analysts have trimmed Zoetis' average price target by roughly $30 to $40 to around the low $100s. This reflects recent target cuts from firms citing softer Q1 results, intensifying competition, and a sharp pullback in the stock that has weighed on investor confidence.Mise à jour du récit • May 26
ZTS: Premium Pet Health Portfolio Will Support Reset Earnings Path Forward
Zoetis' analyst fair value estimate has been reset from $151.00 to about $124.59 as analysts trim price targets after a difficult Q1, rising competitive pressures, and signs that premium pricing is meeting more cautious consumer demand, despite longer term guidance implying improvement. Analyst Commentary Recent research points to a reset in expectations for Zoetis, with target prices broadly trimmed as analysts rework their models around the latest Q1 update, rising competition, and more cautious consumer behavior toward premium products.
Nouveau récit • May 26
Zoetis down -50% over the past year
World's leading animal pharma company at 13x PE with 9% EPS growth Occasionally something crosses my eye which screens well, but after some work is done it isn’t interesting enough to warrant writing about it as a paid article. Zoetis is one such stock.Mise à jour du récit • May 03
ZTS: Share Repurchases And Capital Discipline Will Support Medium-Term Upside
Analysts have modestly trimmed their Zoetis fair value estimate by about $3 to $184, reflecting mixed updates to revenue growth, margins, and long term P/E assumptions after recent shifts in price targets and ratings across the Street. Analyst Commentary Recent research updates on Zoetis reflect a mix of reduced price targets, a downgrade on growth concerns, and fresh bullish coverage.Mise à jour du récit • Apr 19
ZTS: Fair View Weighs Organic Growth Concerns Against Pipeline Execution Risk
Analysts have trimmed the Zoetis fair value estimate by $3 to $127, reflecting a mix of cautious views around organic growth and slightly adjusted assumptions for future P/E, revenue growth, and profitability, even as some firms maintain a bullish stance on the stock. Analyst Commentary Recent Street research around Zoetis shows a split tape, with several bearish analysts focusing on weaker organic growth trends and execution risk, even as others remain constructive on the long term story.Mise à jour du récit • Apr 04
ZTS: Share Repurchases And Execution Recovery Will Support Medium-Term Upside
Analyst targets on Zoetis have shifted modestly, with a small net reduction in the Street price target in dollar terms as some analysts cite concerns about organic growth and an innovation "air pocket," even as others make minor upward adjustments. Analyst Commentary Recent Street research on Zoetis reflects a split view, with some analysts emphasizing concerns around organic growth and an innovation air pocket, while others are adjusting targets in a more constructive way.Mise à jour du récit • Mar 21
ZTS: Future OA Pain Launch And Buybacks Will Support Medium-Term Upside
Narrative Update The updated analyst price target for Zoetis moves from about $197.51 to $187.59, reflecting analysts' mixed views. Some cite softer organic growth and an innovation "air pocket," while others make smaller price target adjustments.Mise à jour du récit • Mar 06
ZTS: Fair View Balances Growth Concerns With Innovation Air Pocket Risk
Zoetis's analyst price target holds steady at $130, as analysts balance concerns about organic growth and an innovation "air pocket" with stable margin expectations and a lower future P/E assumption. Analyst Commentary Recent Street research on Zoetis points to a more cautious tone, with several bearish analysts questioning the near term growth setup and how that lines up with the current valuation.Mise à jour du récit • Feb 20
ZTS: Future Pet Osteoarthritis Pipeline Will Support Premium Multiple Potential
Zoetis' analyst fair value estimate has been reset from $158.22 to $151.00, as analysts balance recent price target changes and a slightly lower assumed future P/E multiple against broadly steady growth and margin assumptions. Analyst Commentary Recent Street research on Zoetis points to a mixed setup, with some analysts seeing support for the current valuation and others focusing on execution risk and the product pipeline.Mise à jour du récit • Feb 06
ZTS: Future OA Pain Launch Execution Will Drive Medium-Term Upside Potential
Analysts have trimmed their Zoetis fair value estimate from about US$200 to roughly US$197.51. This reflects recent price target cuts and more cautious views around product launch headwinds and competition, even as they still see solid margins and a premium P/E as part of the story.Mise à jour du récit • Jan 22
ZTS: Fair Outlook Balances OA Pain Headwinds With New Antibody Approvals
Narrative update on Zoetis The analyst fair value estimate for Zoetis has been reset from US$153 to US$130 as analysts factor in slower expected revenue growth, a slightly higher discount rate, lower assumed future P/E multiples, and ongoing competitive and product launch headwinds highlighted in recent research. Analyst Commentary Recent research on Zoetis has tilted more cautious, with several bearish analysts resetting expectations around growth, execution, and what investors are willing to pay for the stock.Mise à jour du récit • Jan 08
ZTS: Future Product Launches Will Offset Current Competition Pressures
Analysts have trimmed their price targets on Zoetis, reflecting a fair value move from about $170 to $158 as they factor in product launch headwinds, tougher competition in key franchises, and more cautious revenue expectations for 2025 and 2026. Analyst Commentary Recent Street research reflects a mixed but more cautious stance on Zoetis, with several firms trimming price targets and reassessing growth and competitive risks over the next few years.Mise à jour du récit • Dec 15
ZTS: Execution In Animal Health Leadership Will Drive Medium-Term Upside Potential
Analysts have cut their fair value estimate for Zoetis by about $30,000,000,000 to roughly $200,000,000,000, reflecting expectations for slower mid decade revenue growth, modestly lower margins, and a less generous future earnings multiple amid increasing competitive and product launch headwinds. Analyst Commentary Recent Street research reflects a more balanced stance on Zoetis, with fair value expectations reset lower but many firms still highlighting the company as a structural leader in animal health.Mise à jour du récit • Nov 30
ZTS: Earnings Will Recover As Competition Pressures Recent Product Launches
Zoetis's fair value target experienced a modest reduction to $169.96. Analysts highlighted competitive pressures and headwinds from recent product launches as key drivers for the change.Mise à jour du récit • Nov 16
ZTS: Earnings Will Rebound As Volume Pressures Ease In 2026
Zoetis' analyst price target has been reduced from approximately $188 to $171 per share, as analysts cite tempered growth expectations and revised financial assumptions following recent quarterly updates. Analyst Commentary Following Zoetis' latest quarterly updates and subsequent guidance revision, analysts have updated their perspectives on the company's outlook.Mise à jour du récit • Nov 01
ZTS: Global Demand Trends Will Drive Earnings Consistency In Coming Quarters
Narrative Update: Zoetis Analyst Price Target Adjustment Analysts have modestly decreased their price target for Zoetis from $165 to $158, citing a more cautious outlook ahead of upcoming results. Analyst Commentary Analyst perspectives on Zoetis highlight both optimism regarding the company’s long-term fundamentals as well as heightened caution leading into upcoming earnings releases.Mise à jour du récit • Oct 18
Companion Animal And Livestock Demand Will Unlock Future Opportunities
Analysts have slightly lowered their price target for Zoetis from $189.22 to $188.83, citing modest revisions to revenue growth estimates. They also noted a marginal increase in expected profit margins.Mise à jour du récit • Oct 04
Companion Animal And Livestock Demand Will Unlock Future Opportunities
Analysts have slightly lowered their price target for Zoetis from $190.29 to $189.22, citing marginally softer revenue growth and profit margin expectations. What's in the News Zoetis received conditional FDA approval for Dectomax-CA1, the first and only injectable for preventing and treating infestations caused by New World screwworm larvae in cattle.Rendement pour les actionnaires
| ZTS | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | 5.3% | 3.4% | -2.1% |
| 1Y | -50.4% | 54.6% | 18.8% |
Rendement vs Industrie: ZTS a sous-performé le secteur US Pharmaceuticals qui a rapporté 54.6 % au cours de l'année écoulée.
Rendement vs marché: ZTS a sous-performé le marché US qui a rapporté 18.8 % au cours de l'année écoulée.
Volatilité des prix
| ZTS volatility | |
|---|---|
| ZTS Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: ZTS n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de ZTS ( 5% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2012 | 14,500 | Kristin Peck | www.zoetis.com |
Zoetis Inc. se consacre à la découverte, au développement, à la fabrication et à la commercialisation de médicaments, de vaccins, de produits et de services de diagnostic, de biodispositifs, de tests génétiques et de solutions de santé animale de précision pour l'industrie de la santé animale aux États-Unis et à l'étranger. L'entreprise commercialise ses produits principalement pour les animaux de compagnie (chiens, chats et chevaux) et les espèces animales (bovins, porcs, volailles, poissons et moutons). Elle propose également des parasiticides, des vaccins, des produits dermatologiques, des anti-infectieux, des analgésiques et des sédatifs, d'autres produits pharmaceutiques et des diagnostics de santé animale.
Zoetis Inc. Résumé des fondamentaux
| ZTS statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$31.00b |
| Bénéfices(TTM) | US$2.64b |
| Recettes(TTM) | US$9.53b |
12.2x
Ratio P/E3.4x
Ratio P/SLe site ZTS est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| ZTS compte de résultat (TTM) | |
|---|---|
| Recettes | US$9.53b |
| Coût des recettes | US$2.69b |
| Marge brute | US$6.83b |
| Autres dépenses | US$4.20b |
| Les revenus | US$2.64b |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 6.38 |
| Marge brute | 71.74% |
| Marge bénéficiaire nette | 27.69% |
| Ratio dettes/capitaux propres | 288.0% |
Quelles ont été les performances à long terme de ZTS?
Voir les performances historiques et les comparaisonsDividendes
2.7%
Rendement actuel des dividendes34%
Ratio de distributionLe site ZTS verse-t-il des dividendes fiables ?
Voir ZTS l'historique des dividendes et les indices de référence| Zoetis dates des dividendes | |
|---|---|
| Date ex-dividende | Jul 20 2026 |
| Date de paiement du dividende | Sep 01 2026 |
| Jours jusqu'au dividende Ex | 33 days |
| Jours jusqu'à la date de paiement du dividende | 10 days |
Le site ZTS verse-t-il des dividendes fiables ?
Voir ZTS l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/21 00:52 |
| Cours de l'action en fin de journée | 2026/08/21 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Zoetis Inc. est couverte par 39 analystes. 17 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Charles Butler | Barclays |
| Glen Santangelo | Barclays |